Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04601857 · ClinicalTrials.gov registry record · Phase 2
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
A Phase 2 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT04601857 is a Phase 2 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 43 participants.
The verdict
NCT04601857, a Phase 2 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.
Interventions
- DRUG Pembrolizumab
- DRUG Futibatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2025-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04601857
The ClinicalTrials.gov registry entry for NCT04601857 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04601857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04601857 about?
NCT04601857 is a clinical study titled "Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma". The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are...
What is the current status of trial NCT04601857?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2021-01-07. Estimated completion is 2025-09-16.
What interventions are being tested in trial NCT04601857?
The interventions under investigation include: Pembrolizumab (DRUG), Futibatinib (DRUG).
Who is sponsoring clinical trial NCT04601857?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.